Masimo's (NASDAQ:MASI) Q1: Beats On Revenue But Stock Drops

Yahoo

07-05-2025

We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Masimo's recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 7.3% over the last two years.
Reviewing a company's long-term sales performance reveals insights into its quality. Any business can have short-term success, but a top-tier one grows for years. Luckily, Masimo's sales grew at a solid 15.1% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers.
Founded in 1989 to solve the "unsolvable problem" of accurate pulse oximetry during patient movement, Masimo (NASDAQ:MASI) develops and manufactures noninvasive patient monitoring technologies, including its breakthrough pulse oximetry systems that accurately measure blood oxygen levels even during patient movement.
Katie Szyman, Chief Executive Officer of Masimo, said, 'Since joining Masimo as CEO three months ago, I have been focused on immersing myself in our business. I have visited customers, employees, manufacturing and R&D sites, evaluated our innovation pipeline, and attended national meetings with our sales team. My key takeaways are that our technology advantage is real, we have a stellar team that is enthusiastic about the path forward at Masimo, and we have an opportunity to build and improve from a position of meaningful strength. Our first quarter results clearly demonstrate the earnings power of our core business as we delivered double-digit revenue growth and exceptional earnings growth.'
Is now the time to buy Masimo? Find out in our full research report .
Medical tech company Masimo (NASDAQ:MASI) reported Q1 CY2025 results exceeding the market's revenue expectations , but sales fell by 24.5% year on year to $372 million. The company expects the full year's revenue to be around $1.52 billion, close to analysts' estimates. Its non-GAAP profit of $1.36 per share was 12.5% above analysts' consensus estimates.
Story Continues
Masimo Year-On-Year Revenue Growth
We can dig further into the company's sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 5% year-on-year declines. Because this number is better than its normal revenue growth, we can see that foreign exchange rates have been a headwind for Masimo.
Masimo Constant Currency Revenue Growth
This quarter, Masimo's revenue fell by 24.5% year on year to $372 million but beat Wall Street's estimates by 1.1%.
Looking ahead, sell-side analysts expect revenue to decline by 21.8% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Operating Margin
Operating margin is an important measure of profitability as it shows the portion of revenue left after accounting for all core expenses – everything from the cost of goods sold to advertising and wages. It's also useful for comparing profitability across companies with different levels of debt and tax rates because it excludes interest and taxes.
Masimo was profitable over the last five years but held back by its large cost base. Its average operating margin of 7.2% was weak for a healthcare business.
Analyzing the trend in its profitability, Masimo's operating margin decreased by 32.8 percentage points over the last five years. The company's two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 19.5 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn't pass those costs onto its customers.
Masimo Trailing 12-Month Operating Margin (GAAP)
This quarter, Masimo generated an operating profit margin of 21%, up 14.1 percentage points year on year. This increase was a welcome development, especially since its revenue fell, showing it was more efficient because it scaled down its expenses.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company's growth is profitable.
Masimo's EPS grew at a solid 8% compounded annual growth rate over the last five years. However, this performance was lower than its 15.1% annualized revenue growth, telling us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.
Masimo Trailing 12-Month EPS (Non-GAAP)
Diving into Masimo's quality of earnings can give us a better understanding of its performance. As we mentioned earlier, Masimo's operating margin improved this quarter but declined by 32.8 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals.
In Q1, Masimo reported EPS at $1.36, up from $0.77 in the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Masimo's full-year EPS of $4.99 to grow 8.5%.
Key Takeaways from Masimo's Q1 Results
We were impressed by how significantly Masimo blew past analysts' constant currency revenue and EPS expectations this quarter. On the other hand, its EBITDA missed and it lowered its full-year EPS guidance. Zooming out, we think this was a mixed quarter. The market seemed to be hoping for more, and the stock traded down 5.9% to $151.25 immediately after reporting.
So should you invest in Masimo right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.